Proven Oncology and Hematology Expertise
New insights into the molecular biology underlying malignancy have revolutionized the care of patients with cancer. Oncology is entering an era of precision medicine - where patients receive treatments tailored to the specific genetic makeup and biology of their tumors.
The oncology biopharma industry, and the professionals who support this industry, are challenged to remain current on rapid scientific advances and a changing oncology marketplace. During 2012 alone, the US FDA approved seven new anticancer agents, and expanded indications for a further five existing agents.1 The reach of emerging therapies extends across tumor types, impacting research design, treatment decisions, and product market shares. Within this fluid environment, effective communications include the most current perspectives, and consider interrelated basic science and translational research.
Deliverables from Kineticx are grounded in extensive oncology experience including:
- A range of solid tumors and hematologic malignancies
- Traditional chemotherapy, hormonal therapy, and targeted therapies
- Oncology supportive care interventions
- Regular attendance at major oncology conferences
Lee Ann Swenson
